Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer

M. Scarpellini, A. Tononi, E. Pasquini, G. Oliverio, P. P. Fattori, L. Gianni, F. Desiderio, M. Nicolini, A. Ravaioli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The treatment of advanced gastric cancer is unsatisfactory. The response rates for single chemotherapy agents: 5-fluorouracil, mitomycin-c, methotrexate, cisplatin, adriamycin, nitrosoureas and etoposide are approximately 10-25% and response duration ranges from 3 to 6 months. Complete responses with single agents are rare. Combination chemotherapy produces higher response rates, but these responses are short. Recently the combination of etoposide, adriamycin and cisplatin (EAP regimen) has been reported to produce results superior to what have been previouslv reported with other regimens. Twenty-four consecutive patients with locally advanced or metastatic gastric cancer (stage III-IV) were treated between June 1990 and December 1992 with the EAP regimen at our Department. Twenty-two patients were evaluable for response and toxicity. Objective responses were observed in 8 of 22 patients (response rate 36%; 95% confidence interval 17% to 59%). No clinical complete response was found. The median duration of the response was 7 months (range 2 to 22). Myelosuppression represented the primary toxicity associated with the EAP regimen. Grade 4 leukopenia was observed in 4 patients (18%). Grade 3-4 thrombocytopenia was registered in two patients, and grade 3 anemia was detected in 4 patients (18%). The median survival for all patients was 8 months and 12 months for the 8 responding patients. The EAP regimen seems to be an effective chemotherapeutic regimen, but cannot be considered the standard therapy for patients with locally advanced or metastatic gastric cancer, because of the high incidence of moderate to severe myelotoxicity and a response rate and duration of survival similar, but not superior, to those obtained using a less toxic schedule.

Original languageEnglish
Pages (from-to)211-215
Number of pages5
JournalJournal of Chemotherapy
Volume6
Issue number3
Publication statusPublished - 1994

Fingerprint

Etoposide
Doxorubicin
Cisplatin
Stomach Neoplasms
Poisons
Leukopenia
Mitomycin
Combination Drug Therapy
Methotrexate
Fluorouracil
Anemia
Appointments and Schedules
Survival Rate
Confidence Intervals
Drug Therapy
Survival
Incidence
Therapeutics

Keywords

  • advanced gastric cancer
  • cisplatin-doxorubicin-etoposide

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Cite this

Scarpellini, M., Tononi, A., Pasquini, E., Oliverio, G., Fattori, P. P., Gianni, L., ... Ravaioli, A. (1994). Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer. Journal of Chemotherapy, 6(3), 211-215.

Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer. / Scarpellini, M.; Tononi, A.; Pasquini, E.; Oliverio, G.; Fattori, P. P.; Gianni, L.; Desiderio, F.; Nicolini, M.; Ravaioli, A.

In: Journal of Chemotherapy, Vol. 6, No. 3, 1994, p. 211-215.

Research output: Contribution to journalArticle

Scarpellini, M, Tononi, A, Pasquini, E, Oliverio, G, Fattori, PP, Gianni, L, Desiderio, F, Nicolini, M & Ravaioli, A 1994, 'Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer', Journal of Chemotherapy, vol. 6, no. 3, pp. 211-215.
Scarpellini M, Tononi A, Pasquini E, Oliverio G, Fattori PP, Gianni L et al. Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer. Journal of Chemotherapy. 1994;6(3):211-215.
Scarpellini, M. ; Tononi, A. ; Pasquini, E. ; Oliverio, G. ; Fattori, P. P. ; Gianni, L. ; Desiderio, F. ; Nicolini, M. ; Ravaioli, A. / Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer. In: Journal of Chemotherapy. 1994 ; Vol. 6, No. 3. pp. 211-215.
@article{3f253f6cd14147648fe3d8d74365bbfa,
title = "Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer",
abstract = "The treatment of advanced gastric cancer is unsatisfactory. The response rates for single chemotherapy agents: 5-fluorouracil, mitomycin-c, methotrexate, cisplatin, adriamycin, nitrosoureas and etoposide are approximately 10-25{\%} and response duration ranges from 3 to 6 months. Complete responses with single agents are rare. Combination chemotherapy produces higher response rates, but these responses are short. Recently the combination of etoposide, adriamycin and cisplatin (EAP regimen) has been reported to produce results superior to what have been previouslv reported with other regimens. Twenty-four consecutive patients with locally advanced or metastatic gastric cancer (stage III-IV) were treated between June 1990 and December 1992 with the EAP regimen at our Department. Twenty-two patients were evaluable for response and toxicity. Objective responses were observed in 8 of 22 patients (response rate 36{\%}; 95{\%} confidence interval 17{\%} to 59{\%}). No clinical complete response was found. The median duration of the response was 7 months (range 2 to 22). Myelosuppression represented the primary toxicity associated with the EAP regimen. Grade 4 leukopenia was observed in 4 patients (18{\%}). Grade 3-4 thrombocytopenia was registered in two patients, and grade 3 anemia was detected in 4 patients (18{\%}). The median survival for all patients was 8 months and 12 months for the 8 responding patients. The EAP regimen seems to be an effective chemotherapeutic regimen, but cannot be considered the standard therapy for patients with locally advanced or metastatic gastric cancer, because of the high incidence of moderate to severe myelotoxicity and a response rate and duration of survival similar, but not superior, to those obtained using a less toxic schedule.",
keywords = "advanced gastric cancer, cisplatin-doxorubicin-etoposide",
author = "M. Scarpellini and A. Tononi and E. Pasquini and G. Oliverio and Fattori, {P. P.} and L. Gianni and F. Desiderio and M. Nicolini and A. Ravaioli",
year = "1994",
language = "English",
volume = "6",
pages = "211--215",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer

AU - Scarpellini, M.

AU - Tononi, A.

AU - Pasquini, E.

AU - Oliverio, G.

AU - Fattori, P. P.

AU - Gianni, L.

AU - Desiderio, F.

AU - Nicolini, M.

AU - Ravaioli, A.

PY - 1994

Y1 - 1994

N2 - The treatment of advanced gastric cancer is unsatisfactory. The response rates for single chemotherapy agents: 5-fluorouracil, mitomycin-c, methotrexate, cisplatin, adriamycin, nitrosoureas and etoposide are approximately 10-25% and response duration ranges from 3 to 6 months. Complete responses with single agents are rare. Combination chemotherapy produces higher response rates, but these responses are short. Recently the combination of etoposide, adriamycin and cisplatin (EAP regimen) has been reported to produce results superior to what have been previouslv reported with other regimens. Twenty-four consecutive patients with locally advanced or metastatic gastric cancer (stage III-IV) were treated between June 1990 and December 1992 with the EAP regimen at our Department. Twenty-two patients were evaluable for response and toxicity. Objective responses were observed in 8 of 22 patients (response rate 36%; 95% confidence interval 17% to 59%). No clinical complete response was found. The median duration of the response was 7 months (range 2 to 22). Myelosuppression represented the primary toxicity associated with the EAP regimen. Grade 4 leukopenia was observed in 4 patients (18%). Grade 3-4 thrombocytopenia was registered in two patients, and grade 3 anemia was detected in 4 patients (18%). The median survival for all patients was 8 months and 12 months for the 8 responding patients. The EAP regimen seems to be an effective chemotherapeutic regimen, but cannot be considered the standard therapy for patients with locally advanced or metastatic gastric cancer, because of the high incidence of moderate to severe myelotoxicity and a response rate and duration of survival similar, but not superior, to those obtained using a less toxic schedule.

AB - The treatment of advanced gastric cancer is unsatisfactory. The response rates for single chemotherapy agents: 5-fluorouracil, mitomycin-c, methotrexate, cisplatin, adriamycin, nitrosoureas and etoposide are approximately 10-25% and response duration ranges from 3 to 6 months. Complete responses with single agents are rare. Combination chemotherapy produces higher response rates, but these responses are short. Recently the combination of etoposide, adriamycin and cisplatin (EAP regimen) has been reported to produce results superior to what have been previouslv reported with other regimens. Twenty-four consecutive patients with locally advanced or metastatic gastric cancer (stage III-IV) were treated between June 1990 and December 1992 with the EAP regimen at our Department. Twenty-two patients were evaluable for response and toxicity. Objective responses were observed in 8 of 22 patients (response rate 36%; 95% confidence interval 17% to 59%). No clinical complete response was found. The median duration of the response was 7 months (range 2 to 22). Myelosuppression represented the primary toxicity associated with the EAP regimen. Grade 4 leukopenia was observed in 4 patients (18%). Grade 3-4 thrombocytopenia was registered in two patients, and grade 3 anemia was detected in 4 patients (18%). The median survival for all patients was 8 months and 12 months for the 8 responding patients. The EAP regimen seems to be an effective chemotherapeutic regimen, but cannot be considered the standard therapy for patients with locally advanced or metastatic gastric cancer, because of the high incidence of moderate to severe myelotoxicity and a response rate and duration of survival similar, but not superior, to those obtained using a less toxic schedule.

KW - advanced gastric cancer

KW - cisplatin-doxorubicin-etoposide

UR - http://www.scopus.com/inward/record.url?scp=0027993930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027993930&partnerID=8YFLogxK

M3 - Article

C2 - 7983505

AN - SCOPUS:0027993930

VL - 6

SP - 211

EP - 215

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -